FP6Индивидуална стипендия2004–2006

RESPOLMED · Bioresorbable Polymers for Medical Applications

6РП — Действия „Мария Кюри“

Период
2004-03-01 → 2006-02-28
Финансиране от ЕС
169 366 €
Участници
1
Схема
EIF

Линиите свързват координатора с партньорите.

Накратко на български

Биоразградими полимери с нова структура се тестват за използване при медицински импланти за фиксиране на тъкани. Те помагат за постигане на постепенно преминаване от твърдо към гъвкаво състояние по време на разграждането им в тялото.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Final Activity Report Summary - RESPOLMED (Bioresorbable Polymers for Medical Applications)

Bioresorbable polymers for in-vivo biomedical use are heavily dominated by polylactides (PLA) and polyglycolides (PGA). However, current implant polymers based on PLA and PGA are not ideal for hard and soft tissue fixation because of their sudden loss of mechanical properties on degradation process with no continuum of change from inelastic to elastic behaviour. The aim of the project was the preparation of flexible materials based on biodegradable graft copolymers consisting of polyoxanorbornene backbones with PLA side-chains which degrade in such way that their mechanical properties change gradually from a rigid to flexible material before bioresorbtion is complete. A series of novel biodegradable/bioresrobable graft copolymers with different length of polyoxanorbornene backbones with poly(hydroxyacid) side-chains, were synthesised to study the variation in properties of these polymers as a function of degradation under simulated biological conditions. A series of mono- and di-alcohol substituted oxanorbornenes were synthesised and used as initiators for the ring opening polymerisation (ROP) of lactide in the presence of stannous octoate, Sn(Oct)2 to prepare oxanorbornenyl polylactide (PLA) macromonomers. The well-characterised macromonomers were then subjected to ring opening metathesis polymerisation (ROMP) by three well-defined 1st, 2nd and modified 2nd generation Grubbs ruthenium initiators to prepare the target bioresorbable graft copolymers. The most effective Grubbs ruthenium initiator for the ROMP of the macromonomers was found to be the modified 2nd generation ruthenium initiator. Investigation of the target graft copolymers by Size Exclusion Chromatography and NMR spectroscopy showed the presence of some uncapped PLA homopolymer (not attached to an oxanorbornyl group), produced as a side product during the ROP of lactide. Our investigation showed that the presence of PLA homopolymer impurity in the target graft copolymers significantly increases the rate of degradation of the final material. Therefore, we developed a convenient procedure of graft copolymers purification to remove PLA homopolymer from the samples. The target graft copolymers were subjected to degradation in phosphate buffer solution. The degradation studies at two different temperatures, 37C and 50C showed that, as expected, increasing the temperature significantly increased the rate of degradation. Comparison of degradation behaviour of graft copolymers with the same oxanorbornyl backbone and different length of PLA grafts indicated that samples with shorter PLA grafts degrade more slowly. The results also indicated that target graft copolymers with one PLA side chain exhibit fastest rate of degradation. One explanation is that the presence of two PLA side chains on each five membered ring in the backbone chain induces steric hindrance and therefore reduces the rate of degradation. The materials based on pure PLA homopolymer show 80% weight loss in about 80 days whereas the weight loss of our target graft copolymers is 40% over the same time. This clearly demonstrates that the rate of degradation of the PLA is greatly reduced by attaching them (grafting) to a polyoxanorbornene backbone chain. This concept of retardation of degradation was the main objective of this work which has been successfully achieved. The medical device industry as a whole can benefit from the outcome of the research and synthesis of a new class of materials from which to fashion devices for patient benefit.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The aim is to synthesise a series of novel biodegradable polymers consisting of polyoxonorbornene backbones with poly (hydroxyacid) side chains, and to study the variation in physical and mechanical properties of these polymers as a function of degradation under simulated biological conditions. A series of mono- and did-alcohol substituted oxonorbornenes will be synthesised and used as initiators for the ring opening polymerisation of lactate and glycoside to make oxonorbornenyl polyhydroxyacid macro monomers which will then be subjected to ring opening metathesis polymerisation (ROMP) to prepare the target biodegradable polymers. This synthetic approach will give complete control of the side chain and backbone chain lengths. This strategy will allow the study of variables such as the nature of the ROMP fragment, the length and composition of the degradable side chain, the size of the backbone, and the side chain density of the polymer prior to degradation. This project brings together a multi-disciplinary research team to develop bioresorbable polymers, which degrade in such a way that their mechanical properties change gradually from a rigid material to an increasingly flexible material before bioresorption is complete. In this way increasing load is introduced gradually onto the supported bone or tissue, which aids the healing process. This feature, combined with good mechanical properties on implantation would lead to the use of these materials in biomedical applications such as temporary hard and soft tissue fixation. Current implant polymers (polylactide, polyglycolide) do not provide this behaviour, with mass loss resulting in relatively sudden loss of mechanical properties on degradation, but no continuum of change from inelastic to elastic behaviour. The medical device industry as a whole will benefit from the outcome of this new class of materials from which to fashion devices for patient benefit.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз